Pharma at war with Azar?

  • After reporting a 45% increase in quarterly profit Pfizer said “it’s business as normal”.
  • Drug companies have made clear that they’ll never voluntarily reduce prices.
  • The pharma industry has spent more than $216 million on lobbying this year.
  • “Telling companies to voluntarily lower their prices and expecting it to happen on a consistent basis is not a realistic long-term policy proposition,” said Anthony T. LoSasso, a professor of health policy and administration at the University of Illinois at Chicago.

Continue reading

Pharma continues to fan the flames..

KEY TAKEAWAY: After raising prices on all its drugs in 2017 Pfizer has given their CEO  a total 2017 compensation that spiked up 61% to $27.9 million.  At the same time Allergan  rewarded its CEO Brent Saunders with a $32.8 million pay package—an eightfold increase over 2016.  Despite PhRMA’s social media blast about the root cause of drug prices the media have pharma in their sites once again. Continue reading